Sequential Treatment With Immunotherapy and Targeted Therapy Denotes OS Benefit in BRAF-Mutant Melanoma
Source: Onc Live, September 2022
Immunotherapy in the form of ipilimumab (Yervoy) plus nivolumab (Opdivo) followed by the targeted therapy combination encorafenib (Braftovi) plus binimetinib (Mektovi) elicited an overall survival (OS) benefit in patients with untreated BRAF-mutated metastatic melanoma, according to findings from the phase 2 SECOMBIT trial (NCT02631447).
SECOMBIT enrolled patients to 3 arms, where they received targeted therapy followed by immunotherapy (arm A), immunotherapy followed by targeted therapy (arm B), or a sandwich approach of targeted therapy followed by immunotherapy followed by additional targeted therapy (arm C).
The 2-year OS rates were 65% (95% CI, 54%-76%) in arm A, 73% (95% CI, 62%-84%) in arm B, and 69% (95% CI, 59%-80%) in arm C. Additionally, at a median follow-up of 32.2 months (interquartile range, 27.9-41.6), the median OS was not reached in any arm, and the lower bounds of the 95% CI were not estimable. Furthermore, over 30 patients were alive in each arm. Assuming a null hypothesis of median OS of 15 months, all arms met the OS end point.